Sökning: "b-AP15"
Visar resultat 1 - 5 av 13 avhandlingar innehållade ordet b-AP15.
1. Potential New Drugs in Lymphoma
Sammanfattning : Lymphomas are malignant tumours arising from cells in the lymphatic system. They are classified as B-cell lymphomas, T-cell lymphomas and Hodgkin lymphoma (HL). Of the B-cell lymphomas, one of the most common is diffuse large B-cell lymphoma (DLBCL). LÄS MER
2. Studies of b-AP15 : a novel inhibitor of proteasome deubiquitinase activity
Sammanfattning : Bortezomib was the first FDA approved proteasome inhibitor that was initially very successful in treatment of multiple myeloma patients but acquired resistance and adverse side-effect highly decreased patients’ quality of life. Development of 2nd generation proteasome inhibitors that could overcome these shortcomings is thus of prime medical importance. LÄS MER
3. Identification and characterization of a proteasome deubiquitinase inhibitor
Sammanfattning : The 26S proteasome has emerged as an attractive therapeutic target in the treatment of cancers. Proteasome inhibitors have been shown to selectively kill cancer cells. The FDA approval of bortezomib for the treatment of multiple myeloma and mantle cell lymphoma has clinically validated the 26S proteasome as a therapeutic target in oncology. LÄS MER
4. Mechanistic studies of a novel inhibitor of the ubiquitin-proteasome system
Sammanfattning : The ubiquitin-proteasome system (UPS) not only maintains cellular proteostasis, but plays an essential role in multiple vital cellular processes, including survival and growth. Proteasomal inhibitors, such as bortezomib, have been shown to have effective anti-cancer properties, verifying the UPS as a viable drug target in cancer treatment. LÄS MER
5. Studies of overcoming acquired resistance : molecular mechanisms and development of novel drugs
Sammanfattning : Chemotherapeutic agents have become widely applied for treatment of various types of malignancies. Drug resistance unfortunately remains as a major obstacle for the effectiveness of chemotherapy. Cancer drug resistance includes two broad categories: intrinsic and acquired. LÄS MER